<h4>Background</h4>KRAS-mutant non-small cell lung cancer (NSCLC) shows a relatively low response rate to chemotherapy, immunotherapy and KRAS-G12C selective inhibitors, leading to short median progression-free survival, and overall survival. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.